27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer's disease (AD) based on tau pathology. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Before any manifestations of cognitive or behavioral changes, there were differences in resting state connectivity in cognitively normal subjects with brain amyloid deposition, suggesting that early manifestation of Abeta toxicity can be detected using resting state fMRI. 3 key findings →
Participants: 35 Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid deposition is present in 20-50% of nondemented older adults yet the functional consequences remain unclear. 2 key findings →
Participants: 38 Evidence: low
Full summary, score breakdown and related studies → Original source
Despite differing white and grey matter retention characteristics, cortical retention for each (18)F tracer was highly correlated with that of PiB, enabling conversion of thresholds across tracer measurement scales with a high level of internal consistency. 2 key findings →
Participants: 40 Evidence: low
Full summary, score breakdown and related studies → Original source
Individuals with greater early- and middle-life cognitive activity had lower [(11)C]PiB uptake. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Recent evidence suggests that some brain areas act as hubs interconnecting distinct, functionally specialized systems. 5 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive decline is commonly observed in advanced aging even in the absence of disease. 3 key findings →
Participants: 93 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a neurodegenerative disorder that prominently affects cerebral connectivity. 3 key findings →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source
A selective distribution of Alzheimer's disease (AD) pathological lesions in specific cortical layers isolates the hippocampus from the rest of the brain. 3 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
Activity and reactivity of the default mode network in the brain was studied using functional magnetic resonance imaging (fMRI) in 28 nondemented individuals with mild cognitive impairment (MCI), 18 patients with mild Alzheimer's disease (AD), and 41 healthy elderly controls (HC). 3 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
The amygdala is composed of multiple nuclei with unique functions and connections in the limbic system and to the rest of the brain. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Microglia are the resident macrophages of the central nervous system. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
White matter changes in patients with Alzheimer's disease are likely to be secondary to wallerian degeneration of fibre tracts due to neuronal loss in cortical associative areas. 3 key findings →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source
Diffusion tensor imaging (DTI) can detect, in vivo, the directionality of molecular diffusion and estimate the microstructural integrity of white matter (WM) tracts. 1 key finding →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is characterized by a heterogeneous distribution of pathological changes throughout the brain. 2 key findings →
Participants: 36 Evidence: low
Full summary, score breakdown and related studies → Original source
Hereditary diseases are caused by mutations in genes, and more than 7,000 rare diseases affect over 30 million Americans. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Galveston Orientation and Amnesia Test (GOAT) was developed to evaluate cognition serially during the subacute stage of recovery from closed head injury. 1 key finding →
Participants: 50 Evidence: low
Full summary, score breakdown and related studies → Original source
Retinal abnormalities in early AD include a specific pattern of RNFL loss, narrow veins, and decreased retinal blood flow in these veins. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
We show variable degrees of rest-activity circadian dysfunction in AD patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These findings demonstrate that the aging gut microbiota drives detrimental changes in the gut-brain and gut-retina axes suggesting that microbial modulation may be of therapeutic benefit in preventing inflammation-related tissue decline in later life. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our study confirms some other studies in showing that in AD patients there is a reduction of parapapillary and macular RNFL thickness and macular volume as measured by OCT. 5 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source
Distinct patterns of brain atrophy exist in CBDS and PSP that can be used to differentiate the 2 diseases. 4 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source
Our data confirm the retinal involvement in AD, as reflected by loss of axons in the optic nerves. 2 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
Although historically perceived as a disorder confined to the brain, our understanding of Alzheimer's disease (AD) has expanded to include extra-cerebral manifestation, with mounting evidence of abnormalities in the eye. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study indicates that, as a group, GBA mutation-positive individuals show a deterioration in clinical markers consistent with the prodrome of PD. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →